VaxDesign   Report issue

For profit Phase 4
Founded: Orlando FL United States (2003)
Status: Acquired by Sanofi-Aventis (2010)

Organization Overview

First Clinical Trial
2017
NCT04543669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

VaxDesign Corporation

Active Ingredients

Drugs in Phase 4 Trials (1)

tdap (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Whooping Cough (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1